Modified C-terminal growth hormone fragment; investigational metabolic peptide

AOD-9604

aka AOD9604 · Tyr-hGH(177–191) · LAT8881 · LAT-8881

Evidence grade
Grade F: Tested and failed
for fat loss
User score too few reports (6) needs ≥ 10 reports
US FDA Not approved checked 2026-11-13
WADA 2026 Prohibited (S2.2.3) at all times · checked 2026-11-13
EU EMA central marketing authorization not found; LAT8881 has a European clinical-trial results record, which is not authorization. · checked 2026-11-13

Goals: Fat loss Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

0 men

No reports in this group yet.

Everyone

6 people

small sample · n = 6

Outcome unclear 3 of 6 · no effect 2 of 6 · positive 2 of 6

Benefits fat loss 1 of 6 · less appetite 1 of 6 · muscle 1 of 6

Side effects injection site 1 of 6

Stopped 0 of 6 Used with other compounds 4 of 6

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “I can’t tell if there is any effect of AOD.”

  • “took it for 12 weeks lost 25lb but I was in strict calorie deficit.”

  • “The appetite suppression has been a great help on the days that the others started to wear off.”

  • “I recently switched from taking AOD in the morning to the evening...2 hours after I eat, before bed. BAM!”

  • “You don't want to use all Acetic Acid to reconstitute the AOD, because that much acid burns when you inject it.”

Read summaries and method notes

Read 1. No self-reporter in the usable sample supplied both male sex and an age of 45–60. One user reported no discernible AOD effect after two weeks while simultaneously using CJC/ipamorelin and tesamorelin, whereas another described 25 lb lost over 12 weeks while explicitly noting a strict calorie deficit. Another user attributed appetite suppression and improved response to GLP-1 medication to adding AOD, again making attribution inseparable from the stack. The resulting pattern is mixed: some fat-loss/appetite claims, but a clear no-effect case and substantial diet/GLP-1/GH-axis confounding. Reported use ranged from two weeks to twelve weeks, with no useful age-specific evidence.

Read 2. No man aged 45–60. Six users: 1 positive (fat loss after switching to evening dosing), 2 no effect after 2–4 weeks, 3 unclear. One injection-site burn from too much acetic acid; vials often gel. Four of six stacked it with tirzepatide, CJC/ipamorelin or NAD+.

Note 1. Very high confounding from GLP-1s, CJC/ipamorelin, tesamorelin and calorie restriction. Question-only users were not counted.

Note 2. Mostly stacked with tirzepatide or CJC-1295/ipamorelin. Frequent complaints of vial gelling and acetic-acid sting.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Modified growth-hormone fragment Tyr-hGH(177–191). Lipolysis findings in animals do not establish human fat loss or guarantee no glucose/insulin effects. Obesity development ended after the larger randomized trial failed; later research continued as LAT8881. Human safety findings are route- and study-specific, with FDA concerns about immunogenicity, impurities and serious events of uncertain causality. FDA review

Safety

  • Human safety data mainly concern oral or intravenous research formulations, not routine subcutaneous use.
  • Headache, gastrointestinal symptoms and possibly related chest tightness were reported.
  • A serious diarrhea event was considered possibly related; other serious events have uncertain causality.
  • FDA flags immunogenicity, peptide impurities and inadequate characterization.
  • Negative antibody tests in selected trial participants do not establish universal absence of immunogenicity.

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence F fat loss

F stands. The 502-patient OPTIONS trial showed no weight-loss advantage over placebo at 12 or 24 weeks and obesity development was stopped - a direct failure of the marketed use. F here means failed efficacy, not proven harm.

Human trials · 3

  1. not found2005Randomized double-blind placebo-controlled trial; METAOD005; efficacy reported in conference abstract 300 people

    Adults with obesity

    12-week oral study reported a small, nonlinear weight-loss signal; FDA found inadequate reporting to establish meaningful efficacy. Source

  2. not found2007Randomized double-blind placebo-controlled trial; OPTIONS/METAOD006; year of results announcement 502 people

    Adults with obesity; BMI 30–45 kg/m²

    No significant weight-loss advantage at 12 or 24 weeks; obesity development terminated. FDA reports 536 enrolled; the later safety paper reports 534, both with 502 randomized. Source

  3. NCT038659532021Phase 2a randomized double-blind placebo-controlled crossover trial; results posted 2021 53 people

    Adults with neuropathic pain

    LAT8881 did not improve the primary four-week pain endpoint versus placebo (P=0.67); this was not a weight-loss trial.

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    Oral 1–30 mg once daily across randomized dose groups for 12 weeks (METAOD005). Source on a non-primary host — not linked
  • clinical trial
    Oral 0.25–1 mg once daily across randomized dose groups for 24 weeks (OPTIONS/METAOD006). Source on a non-primary host — not linked

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 4.5 out of 5
  • Sleep 2.5 out of 5
  • Recovery not rated —
  • Cognitive not rated —

Sources

  1. fda.gov/media/183584/download
  2. fda.gov/media/183891/download
  3. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  4. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf?embed=
  5. fda.gov/media/185642/download
  6. fda.gov/advisory-committees/advisory-committee-calendar/updated-meeting-time-and-public-pa
  7. fda.gov/media/94155/download
  8. precision.fda.gov/uniisearch/srs/unii/7up768ip4m
  9. pubmed.ncbi.nlm.nih.gov/11146367/
  10. ema.europa.eu/en/medicines
  11. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
  12. clinicaltrials.gov/study/NCT03865953
  13. clinicaltrials.gov/study/NCT04153409
  14. clinicaltrials.gov/study/NCT05298306
  15. ema.europa.eu/en/search?search_api_fulltext=AOD-9604
  16. pubmed.ncbi.nlm.nih.gov/11146367/?format=pubmed

Reddit threads read · 9

3 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.